The partnership is aiming to collect and analyse digital biomarkers to identify signs of response and relapse in Beckley’s upcoming...
Awakn Life Sciences has filed a Patent Cooperation Treaty (PCT) application for the treatment of behavioural addictions with ketamine and ketamine-assisted psychotherapy.
Clerkenwell Health is expanding its pan-European advisory board with the addition of Dr David Erritzoe, Dr Dea Siggaard Stenbæk, Dr Kim Kuypers and Dr James Stone...
Dr Laura Trespidi is joining the Beckley Psytech leadership team as CDO, bringing more than 30 years’ experience in global pharmaceutical and biotechnology companies.
Drug developer Benuvia has received approval from the DEA to manufacture psychedelic Active Pharmaceutical Ingredients (APIs).
Nirvana Life Sciences has announced it is making progress with its Health Canada Dealer’s licence application and its facility development.
Mental wellness company Nue Life Health has announced the completion of its Series A equity financing led by Obvious Ventures.
Numinus’ acquisition of Novamind will see the complementary businesses create a North American platform for psychedelic therapy and research.
Research and drug development company Albert Labs has announced it will begin trading on the CSE.
On International Women’s Day, Psychedelic Health takes a look at just some of the women who are spearheading the psychedelic renaissance in the UK.